volume muscular e umfatorcrucial, criando, assim, uma nova classe de doping[3,6,23].A inibicao damiostatinaA inibicao da atividade da miostatina e um promissormetodo terapeutico para restaurar a massa muscular e a forca.Potentes inibidores de miostatina incluindo afolistatina, amiostatina propeptideo, os anticorpos de miostatina,compostosquimicos e receptores soluveis podem ser beneficospara o desenvolvimento de medicamentos para o tratamentode doencas musculares [24, 25].ConclusaoA miostatina mostrou ter grande importancia na limitacaodo crescimento muscular, porem, suas funcoes emoutros aspectos corporais como o coracao, ainda estamuitoobscura e necessita ser mais estudada. Ainda faltammuitasrespostas em relacao ao ser humano quanto ao bloqueio eaomecanismo de funcionamento da miostatina, deve-se fazeruma analise profunda para saber ate onde e seguro bloquea-lae por que faze-lo.Outro fator preocupante e o uso de substanciasbloqueadorasde miostatina como droga para melhora no desempenhoe na estetica de individuos cujo objetivo nao seja o deauxiliarno combate de patologias. Portanto, e de extrema importanciaa realizacao de mais estudos seguros e confiaveis paraque sejafeito o uso em seres humanos.Referencias1. Rodgers BD, Garikipati DK. Clinical, agricultural, andevolutionarybiology of myostatin: Acomparative review. EndocrineReviews 2008;29:513-342. Schuelke M, Wagner KR, StolzLE, Hubner C, Riebel T, KomenW et al. Myostatin mutationassociated with gross musclehypertrophy in a child. N Engl JMed 2004;350: 2682-8.3. Yamada AK. Hipertrofi a do musculo esqueletico:aspectosfi siologicos, celulares e moleculares. 6a MostraAcademicaUNIMEP [online]. [citado 2009 Jun 13]. Disponivel em URL:http://www.unimep.br4. Wehling M, Cai B, Tidball JG.Modulation of myostatin expressionduring modifi ed muscle use.FASEB J 2000;14:103-10.5. Lee SJ, McPherron AC.Regulation of myostatin activity andmuscle growth. Medical Sciences2001;98:9306-11.6. Artioli GG, Hirata RDC, LanchaJunior AH. Gene therapy,genetic doping and sport:fundaments and implications for thefuture. Rev Bras Med Esporte 2007;13:317-21.7. Carlson CJ, Booth FW, GordonSE. Skeletal muscle myostatinm-RNA expression is fi ber-typespecifi c and increases duringhindlimb unloading. Am J Physiol1999;277:601-6.8. Hill JJ, Qiu Y, Hewick RM,Wolfman NM. Regulation of myostatinin vivo by growth and differentiation factor-associatedserum protein-1: A novel proteinwith protease inhibitor andfollistatin domains. Mol Endocrinol 2003;17:1144-54.9. Rios R, Fernandez-Nocelos S, Carneiro I, Arce VM,Devesa J.Diff erential response toexogenous and endogenous myostatinin myoblasts suggests thatmyostatin acts as an autocrine factorin vivo. Endocrinology2004;145:2795-803.10. Hill JJ, Davies MV, PearsonAA, Wang JH, Hewick RM, WolfmanNM et al. Th e myostatinpropeptide and the follistatinrelatedgene are inhibitory bindingproteins of myostatin innormal serum. J Biol Chem2002;277: 40735-41.11. Tobin JF, Celeste AJ.Myostatin, a negative regulator of musclemass: implications for muscledegenerative diseases. Curr OpinPharmacol 2005;5:328-32.12. Wolfman NM, McPherron AC,Pappano WN, Davies MV,Song K, Tomkinson KN et al.Activation of latent myostatinby the BMP-1/tolloid family ofmetalloproteinases. MedicalSciences 2003;100:15842-6.13. Bogdanovich S, Perkins KJ,Krag TOB, Whittemore LA,Khurana TS. Myostatinpropeptide-mediated amelioration ofdystrophic pathophysiology. FASEBJ 2005;19:543-9.14. Zhu X, Hadhazy M, Wehling M,Tidball JG, McNally EM.Dominant negative myostatinproduces hypertrophy withouthyperplasia in muscle. FEBS Lett2000;474:71-5.15. Bogdanovich S, Krag TOB,Barton ER, Morris LD, WhittemoreLA, Ahima RS et al. Functionalimprovement of dystrophicmuscle by myostatin blockade.Nature 2002;420: 418-21.16. Wagner KR, Liu X, Chang X,Ellen RE. Muscle regenerationin the prolonged absence ofmyostatin. Medical Sciences2005;102:2519-24.17. Lin J, Arnold HB, Della-FeraLA, Azain MJ, Hartzell DL,Baile CA. Myostatin knockout inmice increases myogenesisand decreases adipogenesis.Biochem Biophys Res Commun2002;291:701-6.18. Tay GK, Iaschi SPA, BellingeRHS, Chong FN, Hui J. Th edevelopment ofsequence-based-typing of myostatin (GDF-8)to identify the double musclingphenotype in the goat. SmallRuminant Res 2004;52:1-12.19.